Let's focus on what we can do!

By Disabled People for Disabled People

Thursday, 6 April, 2023

Findings may help optimize therapy if considering Ocrevus

The way Ocrevus (ocrelizumab) affects immune cell profiles of people with multiple sclerosis (MS) varies depending on what treatments they were on previously, a new study shows.

Understanding these differences could help to optimize treatment approaches for MS patients considering Ocrevus, scientists say.

The study, “Previous disease-modifying treatments influence T lymphocyte kinetics in people with multiple sclerosis switching to ocrelizumab,” was published in the Journal of Neuroimmunology.

Read more at: 
Categories :
  • Latest Headlines
  • Multiple Sclerosis
Socials :

Recent posts

Student Profiles Coming Soon...